Difass obtains European patent on usage of antidyslipidaemic compositions on nephritic patients

Difass obtains European patent on usage of antidyslipidaemic compositions on nephritic patients
The 21th February 2018, Difass International obtained patent n. 3007772 entitled “Compositions for use in the treatment of dyslipidaemia in chronic kidney disease” that will last twenty years, until the 12th June 2034.
This is an application patent on use of DIF1STAT®, patented association of components owned by Difass International, in the treatment of dyslipidaemia in nephropathic patients suffering from Chronic Kidney Disease (CKD).
    
Obtaining this patent represents the achievement of an important goal for the company, enhancing the recognition of patentend association DIF1STAT® in Europe, not only for its beneficial effect on cholesterol lowering in general population, but also in the treatment of nephropatic patients.